<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284621</url>
  </required_header>
  <id_info>
    <org_study_id>1245.45</org_study_id>
    <secondary_id>2010-022717-25</secondary_id>
    <nct_id>NCT01284621</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers</brief_title>
  <official_title>Relative Bioavailability of Multiple Oral Doses of BI 10773 (25 mg) and Ramipril (5 mg) Administered Together Compared to Multiple Oral Doses of BI 10773 (25 mg) Alone and Ramipril (5 mg) Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Three Way Crossover, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary objective:To investigate if BI 10773 affects the pharmacokinetics of ramipril and if
      ramipril affects the pharmacokinetics of BI 10773.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of empagliflozin (empa).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Empa: Maximum Measured Concentration (Cmax,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of empagliflozin (empa).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Ramipril: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramipril.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Ramipril: Maximum Measured Concentration (Cmax,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramipril.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Ramiprilat: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramiprilat (active metabolite of ramipril).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Ramiprilat: Maximum Measured Concentration (Cmax,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramiprilat.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Empa: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of empagliflozin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramiprilat: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramiprilat.
Note, predose concentrations for ramipril were all below the limit of quantification (BLQ) and therefore the predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramipril was not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Last Dosing to the Maximum Measured Concentration (Tmax,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Time from last dosing to the maximum measured concentration of the analyte in plasma at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant (λz,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Terminal rate constant in plasma at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T 1/2,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Terminal half-life of the analyte in plasma at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRTpo,ss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Mean residence time of the analyte in the body after oral administration at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance After Extravascular Administration (CL/Fss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Apparent clearance of the analyte in plasma after extravascular administration at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/Fss)</measure>
    <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
    <description>Apparent volume of distribution at steady-state during the terminal phase λz following an extravascular dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Tolerability</measure>
    <time_frame>From drug administration until end of washout period (36 days)</time_frame>
    <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 10773</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet per days for 5 days, oral administration with 240 mL water for each treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 + Ramipril</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>medium dose, oral administration</description>
    <arm_group_label>BI 10773 + Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Medium dose oral administration on day 2-5</description>
    <arm_group_label>BI 10773 + Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>medium dose oral administration</description>
    <arm_group_label>BI 10773</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Low dose oral administration on day 1</description>
    <arm_group_label>BI 10773 + Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Low dose oral administration on day 1</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Medium dose oral administration on day 2-5</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. healthy male and female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.45.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>June 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2014</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, open-label, three period, crossover study. Each treatment period was 8 days, with drug administration on days 1 to 5, and they were separated by a washout period of at least 7 days between drug administrations of 2 subsequent treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empa Alone / Empa + Ramipril / Ramipril Alone</title>
          <description>Patients were administered three treatments in the following order:
Empagliflozin alone
Empagliflozin plus Ramipril
Ramipril</description>
        </group>
        <group group_id="P2">
          <title>Empa Alone / Ramipril Alone / Empa + Ramipril</title>
          <description>Patients were administered three treatments in the following order:
Empagliflozin alone
Ramipril
Empagliflozin plus Ramipril</description>
        </group>
        <group group_id="P3">
          <title>Ramipril Alone / Empa Alone / Empa + Ramipril</title>
          <description>Patients were administered three treatments in the following order:
Ramipril
Empagliflozin alone
Empagliflozin plus Ramipril</description>
        </group>
        <group group_id="P4">
          <title>Ramipril Alone / Empa + Ramipril / Empa Alone</title>
          <description>Patients were administered three treatments in the following order:
Ramipril
Empagliflozin plus Ramipril
Empagliflozin alone</description>
        </group>
        <group group_id="P5">
          <title>Empa + Ramipril / Empa Alone / Ramipril Alone</title>
          <description>Patients were administered three treatments in the following order:
Empagliflozin plus Ramipril
Empagliflozin alone
Ramipril</description>
        </group>
        <group group_id="P6">
          <title>Empa + Ramipril / Ramipril Alone / Empa Alone</title>
          <description>Patients were administered three treatments in the following order:
Empagliflozin plus Ramipril
Ramipril
Empagliflozin alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Required unexpected medical treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Overall</title>
          <description>A randomised, open-label, three period, crossover study. The three treatments administered were
Empagliflozin alone
Ramipril
Empagliflozin plus Ramipril
Each treatment period was 8 days, with drug administration on days 1 to 5, and they were separated by a washout period of at least 7 days between drug administrations of 2 subsequent treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss)</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of empagliflozin (empa).</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Empa: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss)</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of empagliflozin (empa).</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5850" spread="18.1"/>
                    <measurement group_id="O2" value="5680" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by empa alone</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.55</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.05</ci_lower_limit>
            <ci_upper_limit>100.18</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the geometric coefficient of variation (gCV)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Empa: Maximum Measured Concentration (Cmax,ss)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of empagliflozin (empa).</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Empa: Maximum Measured Concentration (Cmax,ss)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of empagliflozin (empa).</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="874" spread="25.9"/>
                    <measurement group_id="O2" value="911" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by empa alone</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.47</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.65</ci_lower_limit>
            <ci_upper_limit>111.77</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Ramipril: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramipril.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ramipril: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramipril.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="37.0"/>
                    <measurement group_id="O2" value="7.27" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by ramipril alone</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>108.14</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.51</ci_lower_limit>
            <ci_upper_limit>116.35</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Ramipril: Maximum Measured Concentration (Cmax,ss)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramipril.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ramipril: Maximum Measured Concentration (Cmax,ss)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramipril.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="45.6"/>
                    <measurement group_id="O2" value="8.97" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by ramipril alone.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>103.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>28.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.73</ci_lower_limit>
            <ci_upper_limit>119.64</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Ramiprilat: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</title>
        <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramiprilat (active metabolite of ramipril).</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ramiprilat: Area Under the Curve at Steady-state Over a Uniform Dosing Interval (AUCτ,ss).</title>
          <description>Area under the concentration-time curve of the analyte in plasma at steady-state over a uniform dosing interval τ, of ramiprilat (active metabolite of ramipril).</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" spread="15.5"/>
                    <measurement group_id="O2" value="85.1" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by ramipril alone</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.67</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>5.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.00</ci_lower_limit>
            <ci_upper_limit>101.42</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Ramiprilat: Maximum Measured Concentration (Cmax,ss)</title>
        <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramiprilat.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ramiprilat: Maximum Measured Concentration (Cmax,ss)</title>
          <description>Maximum measured concentration of the analyte in plasma at steady-state over a uniform dosing interval, τ, of ramiprilat.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="36.8"/>
                    <measurement group_id="O2" value="10.5" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No formal testing, investigation of relative bioavailability. Ratio calculated as empa plus ramipril divided by ramipril alone.</non_inferiority_desc>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.67</ci_lower_limit>
            <ci_upper_limit>104.25</ci_upper_limit>
            <estimate_desc>Standard deviation is actually the gCV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Empa: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</title>
        <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of empagliflozin.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Empa: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</title>
          <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of empagliflozin.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cpre,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="31.0"/>
                    <measurement group_id="O2" value="38.6" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="33.7"/>
                    <measurement group_id="O2" value="45.1" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="29.5"/>
                    <measurement group_id="O2" value="46.4" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="25.5"/>
                    <measurement group_id="O2" value="48.3" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ramiprilat: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</title>
        <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramiprilat.
Note, predose concentrations for ramipril were all below the limit of quantification (BLQ) and therefore the predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramipril was not analysed.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Ramiprilat: Predose Concentration Prior to Administration of the Nth Dose (Cpre,N)</title>
          <description>Predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramiprilat.
Note, predose concentrations for ramipril were all below the limit of quantification (BLQ) and therefore the predose concentration of the analyte in plasma prior to administration of the Nth dose, of ramipril was not analysed.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cpre,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="25.5"/>
                    <measurement group_id="O2" value="1.02" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="21.9"/>
                    <measurement group_id="O2" value="1.31" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="20.7"/>
                    <measurement group_id="O2" value="1.37" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cpre,5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="23.4"/>
                    <measurement group_id="O2" value="1.44" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Last Dosing to the Maximum Measured Concentration (Tmax,ss)</title>
        <description>Time from last dosing to the maximum measured concentration of the analyte in plasma at steady state.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Last Dosing to the Maximum Measured Concentration (Tmax,ss)</title>
          <description>Time from last dosing to the maximum measured concentration of the analyte in plasma at steady state.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="42.6" lower_limit="0.667" upper_limit="3.00"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="1.50" spread="44.7" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="0.333" spread="36.4" lower_limit="0.333" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.333" spread="39.1" lower_limit="0.333" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="2.00" spread="23.8" lower_limit="1.48" upper_limit="4.02"/>
                    <measurement group_id="O3" value="2.00" spread="29.4" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant (λz,ss)</title>
        <description>Terminal rate constant in plasma at steady-state</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant (λz,ss)</title>
          <description>Terminal rate constant in plasma at steady-state</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="37.9"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="0.050" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="0.261" spread="107"/>
                    <measurement group_id="O3" value="0.298" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="0.0095" spread="24.1"/>
                    <measurement group_id="O3" value="0.0091" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (T 1/2,ss)</title>
        <description>Terminal half-life of the analyte in plasma at steady-state.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T 1/2,ss)</title>
          <description>Terminal half-life of the analyte in plasma at steady-state.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="37.9"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="13.9" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="2.66" spread="107"/>
                    <measurement group_id="O3" value="2.32" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="73.2" spread="24.1"/>
                    <measurement group_id="O3" value="76.2" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRTpo,ss)</title>
        <description>Mean residence time of the analyte in the body after oral administration at steady-state.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRTpo,ss)</title>
          <description>Mean residence time of the analyte in the body after oral administration at steady-state.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="18.0"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="9.68" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="1.29" spread="54.2"/>
                    <measurement group_id="O3" value="1.42" spread="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="44.7" spread="29.9"/>
                    <measurement group_id="O3" value="47.1" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance After Extravascular Administration (CL/Fss)</title>
        <description>Apparent clearance of the analyte in plasma after extravascular administration at steady-state.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance After Extravascular Administration (CL/Fss)</title>
          <description>Apparent clearance of the analyte in plasma after extravascular administration at steady-state.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="18.1"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="163" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="12600" spread="37.0"/>
                    <measurement group_id="O3" value="11500" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="955" spread="15.5"/>
                    <measurement group_id="O3" value="979" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase (Vz/Fss)</title>
        <description>Apparent volume of distribution at steady-state during the terminal phase λz following an extravascular dose.</description>
        <time_frame>0 hours (h), 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after drug administration on day 5. In addition pre-dose samples, 5 minutes predose, were collected on days 1 to 4</time_frame>
        <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase (Vz/Fss)</title>
          <description>Apparent volume of distribution at steady-state during the terminal phase λz following an extravascular dose.</description>
          <population>Pharmacokinetic (PK) set: All subjects who took at least one dose of investigational treatment and provided at least one observation for at least one primary endpoint without important protocol violations relevant to the PK evaluation.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total empa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="31.8"/>
                    <measurement group_id="O2" value="NA">Not applicable - no ramipril in this treatment arm</measurement>
                    <measurement group_id="O3" value="196" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramipril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="2910" spread="89.1"/>
                    <measurement group_id="O3" value="2310" spread="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ramiprilat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not applicable - no empagliflozin in this treatment arm</measurement>
                    <measurement group_id="O2" value="6050" spread="32.0"/>
                    <measurement group_id="O3" value="6460" spread="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Tolerability</title>
        <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
        <time_frame>From drug administration until end of washout period (36 days)</time_frame>
        <population>Treated set which included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Empa Alone</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Alone</title>
            <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
          <group group_id="O3">
            <title>Empa + Ramipril</title>
            <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Tolerability</title>
          <description>Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment tolerability by the investigator. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
          <population>Treated set which included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment duration plus following washout period (36 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empa Alone</title>
          <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5.</description>
        </group>
        <group group_id="E2">
          <title>Ramipril Alone</title>
          <description>A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
        </group>
        <group group_id="E3">
          <title>Empa + Ramipril</title>
          <description>Empagliflozin 25mg (Empa) was administered once daily from day 1 to day 5. A single dose of ramipril 2.5mg was administered on day 1. Ramipril 5mg was administered once daily from day 2 to day 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

